GlassScriptPhysician profile
Toni Lynette Clark
NPI 1851808190
$6,483.49
in general payments reported to CMS, 2019-2025
42 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,052 · 2022: $1,338 · 2023: $1,292 · 2024: $1,174 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.24 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,172.37 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $717.36 | 2021-2025 | Zerbaxa, Dificid, Pifeltro |
| Theratechnologies INC. | $690.07 | 2021-2025 | Trogarzo, Egrifta |
| Viiv Healthcare Company | $441.70 | 2021-2025 | Rukobia, Cabenuva, Dovato |
| Paratek Pharmaceuticals, INC. | $407.87 | 2021-2025 | Nuzyra |
| Averitas Pharma INC. | $343.95 | 2024-2025 | Qutenza |
| Insmed, INC. | $305.28 | 2023-2025 | Arikayce, Brinsupri |
| Aimmune Therapeutics, INC. | $277.05 | 2023-2025 | Vowst, Zenpep |
| Janssen Biotech, INC. | $226.12 | 2021-2023 | Symtuza |
| Abbvie INC. | $224.80 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $206.08 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.57 | 2021-2025 | Cuvitru, Hyqvia |
| Organogenesis INC. | $130.44 | 2021 | |
| Next Science LLC | $110.46 | 2023-2024 | Surgx, Xperience, Blastx |
| Smith+Nephew, INC. | $100.57 | 2022-2025 | Collagenase Santyl, Regranex |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $85.28 | 2022 | |
| Pfizer INC. | $85.19 | 2021-2022 | |
| Mimedx Group, INC. | $80.53 | 2024-2025 | |
| Convatec INC. | $58.87 | 2024-2025 | |
| Shionogi INC | $55.92 | 2021-2025 | Fetroja |
| Kci USA, INC. | $52.41 | 2021-2022 | |
| Hartmann USA, INC. | $48.81 | 2021-2025 | Zetuvit Plus 10x10 P10 |
| Grt US Holding, INC. | $45.04 | 2022 | |
| Reprise Biomedical, INC. | $43.06 | 2025 | Miro3d |
| Acera Surgical, INC. | $41.85 | 2022 | |
| Mayne Pharma Commercial LLC | $40.04 | 2021 | |
| Melinta Therapeutics, LLC | $39.05 | 2022-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Medtronic, INC. | $35.81 | 2021 | |
| Tactile Systems Technology INC | $30.37 | 2025 | Flexitouch Plus, Nimbl |
| Cumberland Pharmaceuticals, INC. | $30.17 | 2025 | Vibativ |
| Edwards Lifesciences Corporation | $26.75 | 2022 | |
| Medline Industries LP | $23.03 | 2021 | |
| Cipher Pharmaceuticals US LLC | $19.07 | 2025 | Natroba, Spinosad |
| Cgg Medical INC | $18.77 | 2021 | |
| Hydrofera LLC | $17.71 | 2022 | |
| Cashflow Solutions, LLC | $17.18 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Solventum Corporation | $15.47 | 2024 | V.A.C. Dermatac, Activ.A.C. |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Lifenet Health | $14.10 | 2023 | |
| Emd Serono, INC. | $13.55 | 2025 | |
| Electromed, INC. | $12.94 | 2021 | |
| Advanced Oxygen Therapy INC. | $7.83 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.